New drug combo takes on advanced cancers in early human test

NCT ID NCT05701527

Recruiting now Disease control Sponsor: EDDC (Experimental Drug Development Centre), A*STAR Research Entities Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called EBC-129, both by itself and together with the immunotherapy pembrolizumab, in people with advanced solid tumours that have stopped responding to standard treatments. The study will enroll about 98 adults and focus mainly on safety, side effects, and finding the right dose. Researchers will also look for early signs of tumour shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EBC-129 (an experimental drug) and pembrolizumab (an immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumours who have run out of standard therapies.
What could go wrong: This is an early Phase 1 trial with only 98 participants, so the main goal is safety, not effectiveness. The drug may not shrink tumours or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOURS

Contacts and locations

Locations

National Cancer Centre Singapore
RECRUITING

Singapore, South West, 168583, Singapore
National University Hospital - Medical Oncology
RECRUITING

Singapore, South West, 119228, Singapore
Taipei Veterans General Hospital
NOT_YET_RECRUITING

Taipei, Taipei, 11217, Taiwan
UT MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center
RECRUITING

Aurora, Colorado, 80045-2517, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.